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A B S T R A C T
Purpose
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recentin in
Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib,
an oral pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as
monotherapy or in combination with lomustine versus lomustine in patients with recurrent glio-
blastoma.
Patients and Methods
Patients (N  325) with recurrent glioblastoma who previously received radiation and
temozolomide were randomly assigned 2:2:1 to receive (1) cediranib (30 mg) monotherapy; (2)
cediranib (20 mg) plus lomustine (110 mg/m2); (3) lomustine (110 mg/m2) plus a placebo. The
primary end point was progression-free survival based on blinded, independent radiographic
assessment of postcontrast T1-weighted and noncontrast T2-weighted magnetic resonance
imaging (MRI) brain scans.
Results
The primary end point of progression-free survival (PFS) was not significantly different for either
cediranib alone (hazard ratio [HR]  1.05; 95% CI, 0.74 to 1.50; two-sided P  .90) or cediranib in
combination with lomustine (HR  0.76; 95% CI, 0.53 to 1.08; two-sided P  .16) versus
lomustine based on independent or local review of postcontrast T1-weighted MRI.
Conclusion
This study did not meet its primary end point of PFS prolongation with cediranib either as
monotherapy or in combination with lomustine versus lomustine in patients with recurrent
glioblastoma, although cediranib showed evidence of clinical activity on some secondary end
points including time to deterioration in neurologic status and corticosteroid-sparing effects.
J Clin Oncol 31:3212-3218. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Despite recent advances in radiation and neuro-
surgical techniques and the approval of newmed-
ical therapies, glioblastoma, the most common
primary malignant brain tumor in adults, causes
significant neurologic morbidity and is associated
with survival of less than 2 years.1,2 Microvascular
proliferation, apathologichallmarkof glioblastoma,
is due to the high expression of proangiogenic
cytokines, particularly of vascular endothelial
growth factor (VEGF) and signaling via its endo-
thelial tyrosine kinase receptor VEGFR2.3-6 Levels
of VEGF and its receptor are correlated with the
histologic grade of gliomas, with the highest levels
present in glioblastoma.7,8Thus glioblastoma has
emerged as an attractive tumor in which to con-
duct clinical trials of novel anti-VEGF agents,
such as monoclonal antibodies and tyrosine
kinase inhibitors.9Bevacizumab, an anti-VEGF
monoclonal antibody, was approved as mono-
therapy for recurrent glioblastoma by the US
Food and Drug Administration in 2009 based on
the radiographic response rates in two phase
II trials.10-12
Cediranib is an orally available pan-VEGFR ty-
rosine kinase inhibitor with a half-life of 22 hours
compatible with once daily dosing. Cediranib has a
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sub-nanomolar half maximal inhibitory concentration for VEGF re-
ceptors with additional activity against c-Kit and lower potency
against platelet-derived growth factor .13 In a prior phase II study of
cediranib (45 mg/d) for patients with recurrent glioblastoma, eight
(27%) of 30 subjects achieved a partial radiographic response based
on consensus-based response criteria.14,15 Subsequently, this interna-
tional, phase III, randomized, partially blinded, placebo-controlled study
was conducted to investigate the efficacy of cediranib, as monotherapy
and in combination with the synthetic alkylating agent lomustine (1-(2-
chloroethyl)-3-cyclohexyl-1-nitrosourea), versus lomustine alone in pa-
tientswith recurrent glioblastoma.
PATIENTS AND METHODS
Patients
Patients with recurrent glioblastoma were the target population for this
study. Inclusion criteria included age  18 years, pathologic diagnosis of
glioblastoma, prior treatment with a temozolomide-containing chemothera-
py regimen, prior treatment with radiation, Karnofsky performance status
(KPS)  70, Mini-Mental Status Examination score  15, and life expec-
tancy 12weeks. Exclusion criteria included any prior anti-VEGF therapy or
cranial radiation within 3 months before study entry. All patients were re-
quired to sign an informed consent form approved by the institutional review
board of the enrolling institution.
Thestudywasperformed inaccordancewith theDeclarationofHelsinki,
the International Conference on Harmonization/Good Clinical Practice, ap-
plicable (national) regulatory requirements, and the AstraZeneca policy
on bioethics.
Trial Design and Treatments
The study was a phase III, comparative, randomized, parallel group,
multicenter trial with patients randomly assigned (stratified by age and resec-
tion status) in a 2:2:1 ratio to receive cediranib (30 mg) monotherapy, cedi-
ranib (20mg) in combinationwith lomustine (110mg/m2), or lomustine (110
mg/m2) in combinationwith a placebo. Cediranib doses (20mg, 30mg)were
givenoncedaily asoral tablets, lomustinedoses (110mg/m2)weregivenasoral
capsules once every 6 weeks, and cediranib-matched placebo was given once
daily as oral tablets. The primary end point of the study was to compare the
efficacy of cediranib, as monotherapy and in combination with lomustine,
with lomustine alone by independent, treatment arm–blinded, radiographic
assessment of progression-free survival (PFS). Secondary objectives included
assessments of the proportion of patients alive and progression-free at 6
months (APF6) after randomization, overall survival (OS), radiographic re-
sponse rate, corticosteroid-sparing effects, time to deterioration in neurologic
status (TTNS), safety, and tolerability. Exploratory end points included the
time to deterioration inKPS and changes frombaseline in the levels of soluble
markers of angiogenesis and tumor growth.
Evaluations
TheprimaryPFSendpointsweredetermined inpatients ona stabledose
of corticosteroids, based on postcontrast, T1-weighted brain magnetic reso-
nance imaging (MRI) scans assessed by independent, centralized, treatment
arm-blinded, radiographic review. The central PFS assessment took cortico-
steroid dose and timing of scans into account. The PFS end points were also
assessed by local review of postcontrast, T1-weighted MRI brain scans by the
treating physicians as well as independent, centralized, treatment-arm
blinded, radiographic review of T2/fluid-attenuated inversion recovery MRI
brain scanson thebasis of published criteria.16,17 Forpatientswithmeasurable
disease at study entry (defined as contrast-enhancing tumor with a shortest
diameter of 10 mm on two axial slices), progression was defined as either
Assessed for eligibility 
(N = 423)
Patients randomly assigned 
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   Voluntary discontinuation
   Death
(n = 98)
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Fig 1. CONSORT diagram. ITT, intent to treat.
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(1)  25% increase in the sum of the products of the largest perpendicular
diameters for all lesions compared with the nadir scan (provided that the
shortest diameter was 15mmat the time of progression); (2) detection of a
new lesion, with shortest diameter of  10 mm, outside the original tumor
volume; (3) death from any cause. For postsurgical patients without measur-
able disease at study entry, progressionwas defined as either (1) detection of a
new lesion; (2) a significant increase in lesion size (to a shortest diameter of
 15mm) for a small, baseline enhancing lesion at study entry; (3) death from
any cause. Theneurologic status andKPSwere based onphysical examination
by the treating investigator before and during treatment. Corticosteroid doses
were recorded for all subjects. Plasma samples obtained at baseline andduring
the study were used to determine levels of the soluble biomarkers VEGF,
sVEGFR2, and basic fibroblast growth factor (bFGF) and to calculate changes
from baseline levels. Adverse events (AEs) were recorded and graded accord-
ing to the Common Terminology Criteria for Adverse Events (CTCAE) ver-
sion 3.0.
Statistical Analysis
The primary end point of the study was PFS based on centralized,
radiographic review. Secondary end points were OS, response rate in patients
with measurable disease, APF6, time to deterioration in neurologic status,
meanchange inaveragedailydosageof corticosteroids, andaveragenumberof
progression- and corticosteroid-free days. Assuming a true hazard ratio (HR)
of 0.55, with 300 patients randomly assigned 2:2:1 to cediranib, cediranib plus
lomustine, and lomustine plus placebo, the trial hadmore than 80%power to
demonstrate a statistically significant difference in PFS at a two-sided, 2.5%
level. This would correspond to an 80% increase in PFS if median time to
progression was 3 months in the lomustine-alone arm. The analysis for PFS
was planned after 230 progression events had occurred. PFS was analyzed
using the log-rank test, stratified by resection status and age, and the HR of
progression and associated 95%CIs were estimated from a Cox proportional
hazards model using stratification levels as covariates. Each cediranib-
containing armwas independently comparedwith the lomustine plus placebo
arm. Statistical significance would be declared if both comparisons were sig-
nificant at the two-sided 5% level or if either comparison was statistically
significant at the two-sided 2.77% level. OS was planned to be analyzed
twice—at the timeofPFSanalysis andagainwhen270deathshadoccurred.To
maintain an overall type I error rate of 5%, the significance level was prespeci-
fied at 0.00785 (two-sided) at interim for both comparisons and at 0.00417
(two-sided) at interim for either comparison. All efficacy assessments were
performed on the intent-to-treat randomly assigned population.
RESULTS
Patients
Between October 2008 and September 2009, 325 patients were
randomly assigned in a ratio of 2:2:1 to receive cediranib (30 mg)
monotherapy (n  131), cediranib (20 mg) plus lomustine (110
mg/m2)n129), or lomustine (110mg/m2)plusplacebo (n65).A
CONSORT diagram is included in Figure 1. The demographic and
baseline clinical characteristicswere generallywell-balancedacross the
three arms, although fewer patients in the lomustine plus placebo arm
had KPS less than 80 and used corticosteroids at baseline (Table 1).
Efficacy Outcomes
The primary end point of PFS was not significantly different for
either cediranib alone or in combination with lomustine versus lo-
mustine alone. For the cediranib (30 mg) monotherapy arm, the HR
versus lomustine was 1.05 (95% CI, 0.74 to 1.50; two-sided P .90).
For the cediranib (20mg) plus lomustine arm, the HR versus lomus-
tine was 0.76 (95% CI, 0.53 to 1.08; two-sided P .16). The median
PFS for the cediranib (30 mg) monotherapy arm, the cediranib (20
mg) plus lomustine arm, and the lomustine arm was 92 days (first
quartile  80 days, third quartile  128 days), 125 days (first quar-
tile 83 days, third quartile 201 days), and 82 days (first quartile
42 days, third quartile  168 days), respectively (Fig 2). Compared
with the lomustine arm, neither cediranib-containing arm demon-
strated a significant improvement in PFS based on either central
review of postcontrast T1-weighted or noncontrast T2/ fluid-
attenuated inversion recovery brain MRI scans or local review of
postcontrast T1-weightedbrainMRI scans.At the timeof the primary
PFS analysis, approximately 73% (197 of 270) of the death events
prespecified for final analysis had occurred. At this time, there was no
significant difference in the secondary end point of OS for either
cediranib-containing armversus the lomustine arm.For the cediranib
(30 mg) monotherapy arm, the HR versus lomustine was 1.43 (95%
CI, 0.96 to 2.13; two-sided P .10). For the cediranib (20 mg) plus
lomustine arm, the HR versus lomustine was 1.15 (95% CI, 0.77 to
1.72; two-sided P .50). The median OS for the cediranib (30 mg)
monotherapy arm, the cediranib (20mg)plus lomustine arm, and the
lomustine arm was 8.0 months, 9.4 months, and 9.8 months, respec-
tively (Fig 3). On the basis of predictive power calculations, there was
less than a 0.01% chance of concluding a positive outcome at the final
OS analysis; thus it was considered of no value to continue to final
analysis. A total of 136 patients received postprogression anticancer
therapy, with the majority receiving bevacizumab either as mono-
therapy or in combination. Postprogression bevacizumab utilization
was similar in the cediranib (20 mg) plus lomustine (43 of 84, 51%)
and the lomustine plus placebo (20 of 39, 51%) arms but was less
frequent in thecediranib(30mg)open-label,monotherapyarm(22of
81, 27%).
There were no differences in the radiographic response rates
between the two cediranib-containing arms (Table 2). The median
reduction in contrast-enhanced tumor area was36% and28% in
Table 1. Baseline Characteristics
Characteristic
Cediranib
(n  131)
Cediranib 
Lomustine
(n  129)
Lomustine
 Placebo
(n  65)
No. % No. % No. %
Median age, years 54.0 54.0 54.0
Resection for recurrent
disease
Yes 50 38.2 49 38.0 24 36.9
No 81 61.8 80 62.0 41 63.1
Karnofsky performance
status
 70 0 1 0.8 1 1.6
70-80 65 50.0 62 48.0 23 36.2
90-100 65 50.0 66 51.2 40 62.5
Corticosteroid use at
baseline
Yes 64 48.9 71 55.0 26 40.0
No 67 51.1 58 45.0 39 60.0
Time from last radiotherapy
to randomization,
months
0-3 2 1.5 4 3.1 0
3-6 32 24.4 29 22.5 16 24.6
6-12 52 39.7 42 32.6 27 41.5
 12 45 34.4 54 41.9 22 33.8
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the cediranib (30 mg) monotherapy and cediranib (20 mg) plus lo-
mustine arms, respectively, compared with a 14% increase in the
lomustine plus placebo arm (Fig 4). The APF6 proportions in the
cediranib (30 mg) monotherapy, cediranib (20 mg) plus lomustine,
and lomustine arms were 16%, 35%, and 25%, respectively. Cortico-
steroidusagewas reduced in thecediranib-containingarmscompared
with the lomustine arm; the mean change in corticosteroid use from
baseline to progression was26% for the cediranib (30 mg) mono-
therapy arm (P .01 v lomustine),23% for the cediranib (20 mg)
plus lomustine arm (P .01 v lomustine), and5% for lomustine.
The TTNS HRs for the cediranib (30 mg) monotherapy arm and the
cediranib (20 mg) plus lomustine arm versus lomustine were 0.82
(95% CI, 0.55 to 1.22; P .57) and 0.63 (95% CI, 0.42 to 0.95; P
.01), respectively. The time to deterioration of KPS HRs for the cedi-
ranib (30 mg) monotherapy arm and the cediranib (20 mg) plus
lomustine arm versus lomustine were 1.03 (95%CI, 0.65 to 1.62) and
0.73 (95%CI, 0.45 to 1.17), respectively.
Soluble Biomarkers
Median baseline levels of VEGF were 74 pg/mL (first quartile
47, third quartile 149), 76 pg/mL (first quartile 46, third quar-
tile 165), and 66 pg/mL (first quartile 34, third quartile 93) in
the cediranib 30 mg, cediranib 20 mg plus lomustine, and lomustine
arms, respectively. Median VEGF levels in the cediranib 30-mg arm
increased to 89%, 108%, and 106% above baseline at days 42, 84, and
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Table 2. Best Overall Response (central review postcontrast T1)
Best Overall
Response
Cediranib
(n  118)
Cediranib 
Lomustine
(n  122)
Lomustine 
Placebo
(n  56)
No. % No. % No. %
Responders 18 15.3 21 17.2 5 8.9
CR 1 0.8 2 1.6 0
PR 17 14.4 19 15.6 5 8.9
Stable disease 76 64.4 67 54.9 23 41.1
Unconfirmed CR 0 1 0.8 0
Unconfirmed PR 32 27.1 9 7.4 2 3.6
PD 10 8.5 19 15.6 41.1
Nonevaluable 14 11.9 14 11.5 5 8.9
Abbreviations: CR, complete response; PD, progressive disease; PR,
partial response.
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126, respectively. By contrast, in the lomustine arm, median VEGF
levels at day 42 were similar to those at baseline and decreased by
21%at day 84. An increase inVEGF levels was also recorded at each
time point in the cediranib 20 mg plus lomustine arm (day 42,
46%; day 84, 41%; day 126, 61%), although thesemedian increases
were lower than those for the cediranib 30-mg arm. Subgroup
analyses showed that baseline VEGF levels did not have a signifi-
cant effect on either PFS or OS outcome. Median baseline levels of
sVEGFR2 were similar in the three arms (range, 10,937 to 11,790
pg/mL). At day 42, decreases in median sVEGFR2 levels from
baseline of 27% and 22% were recorded for the cediranib 30 mg
and cediranib 20 mg plus lomustine arms, respectively; these de-
creases were maintained in both arms at days 84 and 126. Median
sVEGFR2 levels in the lomustine arm remained similar to baseline
levels throughout the trial. Median baseline levels of bFGF were 5
pg/mL, 4 pg/mL, and 3 pg/mL in the cediranib 30mg, cediranib 20
mg plus lomustine, and lomustine arms, respectively. No consis-
tent changes from baseline in bFGF levels were seen in any arm. At
day 84, increases of 100% and 80%were observed in the lomustine
arm and the cediranib 20 mg plus lomustine arm, respectively, but
these increases were not maintained at day 126.
Dose-Intensity
The dose-intensity of cediranib was well maintained, and there
was no evidence of early discontinuation before progression in either
cediranib-containing arm. The mean dose-intensity was consistent
(80%) during the first 3 months of therapy. There were more cedi-
ranib dose interruptions in the cediranib (20mg) plus lomustine arm
versus the cediranib (30mg)monotherapy arm.However, there were
more cediranib dose reductions in the cediranib (30 mg) mono-
therapy armversus the cediranib (20mg)plus lomustine arm, and the
majority of reductions occurred after 3months. The incidence of dose
interruptions and reductions of lomustinewas higher in combination
withcediranib comparedwithplacebo (although thenumberof cycles
of lomustine received was generally greater in the combination arm,
reflecting later progressions comparedwith the placebo arm). At least
one dose interruption of lomustine occurred in 27%of patients in the
placebo arm versus 40% in combination with cediranib. The dose of
lomustine was reduced in 50% of subjects on the lomustine plus
placebo arm versus 70% of subjects on the lomustine plus cedi-
ranib arm.
Safety and Tolerability
There were no unexpected AEs observed in any arm during the
course of the study. There was no increased risk of intracranial bleed-
ingobserved in thecediranib-containingarms.Themost commonAE
was diarrhea, experienced by 71%, 71%, and 19% of patients in the
cediranib monotherapy, cediranib plus lomustine, and lomustine
arms, respectively. AEs grade 3 were experienced by a higher pro-
portion of patients in the cediranib plus lomustine arm (80%) com-
pared with the cediranib monotherapy and lomustine arms (61% in
each arm; Table 3). Grade 3 or 4 thrombocytopenia and neutropenia
were observed in 38% and 20%, respectively, of patients in the cedi-
ranib combination arm compared with 2% and 1%, respectively, in
the cediranibmonotherapy arm and 22%and 3%, respectively, in the
lomustine arm.
Serious AEs were observed in 43%, 37%, and 41% of patients in
the cediranibmonotherapy, cediranib plus lomustine, and lomustine
arms, respectively. AEs leading to permanent discontinuation of cedi-
ranib or placebo were observed in 15%, 18%, and 16% of patients in
the cediranibmonotherapy, cediranib plus lomustine, and lomustine
arms, respectively.
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Fig 4. Best change from baseline in contrast-enhancing area. (A) Cediranib; (B) cediranib plus lomustine; (C) placebo plus lomustine.
Batchelor et al
3216 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 165.225.104.129 on September 19, 2019 from 165.225.104.129
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
DISCUSSION
TheREGALtrial failed tomeet itsprimaryendpointofdemonstrating
a benefit in PFS for either cediranib-containing arm versus lomustine
in patients with recurrent glioblastoma. Cediranib demonstrated
some clinical activity in certain secondary end points, including sig-
nificant reduction of corticosteroid usage in both cediranib-
containing arms, and therewas a favorable delay in time toneurologic
deterioration in the cediranib plus lomustine arm versus lomustine.
Therewasnodifference inOSbetween the threearms.AlthoughOSmay
have been confounded by the use of postprogression bevacizumab ther-
apy, bevacizumab use was similar between the cediranib 20 mg plus
lomustine and placebo plus lomustine arms. Expected, dose-dependent
increases in VEGF and decreases in sVEGFR2 were observed in the
cediranib-containingarmsbutnotinthelomustinearm.Baselinelevelsof
these soluble biomarkers were not predictive of outcome in this trial.
Dose-intensity of cediranib was well maintained in the cediranib-
containing arms, although there weremore lomustine reductions in the
cediranibplus lomustine armversus the lomustine armdespite the lower
dose of cediranib (20 mg) in the lomustine plus cediranib arm. The AE
profileobserved inREGALwas consistentwithprior cediranib trials, and
no unexpected AEs were observed. However, patients in the cediranib
plus lomustinearmexperiencedahigher incidenceof toxicities, especially
hematologic adverse effects, compared with the cediranib monotherapy
and lomustine arms.This suggests that the combinationof cediranib and
lomustine exacerbates lomustine-inducedhematologic toxicities.The in-
creased incidence of toxicities did not result in an increase of cediranib
discontinuations, suggesting that the toxicities weremanageable. Impor-
tantly, no increased risk of intracranial bleeding was noted in patients
receiving cediranib.
The combinationdoseof cediranib (20mg)was reduced from30
mg after results from the National Cancer Institute of Canada BR24
study of metastatic lung carcinoma suggested a higher fatality rate in
the cediranib-containing arms at this dose level.18 Whether selection
of a lowerdoseof cediranib in theREGALstudymayhave contributed
to the negative results of the study is impossible to determine.
Lomustine was approved in 1977 for use in patients with brain
tumors.19,20 In a phase I study it was observed that lomustine 130
mg/m2 in combination with cediranib (20mg) was insufficiently well
tolerated in the population of patients with recurrent glioblastoma
who had received prior temozolomide therapy. The dose-limiting
toxicities were hematologic. It was determined that the optimal com-
bination dose of lomustine for REGAL was 110 mg/m2, a dose also
used in other studies in this patient population.21 The PFS and APF6
observed in the lomustine arm in the REGAL study were higher than
the metrics typically used for comparative purposes from historical
series of therapies for this patient population but consistent with that
observed for lomustine inanothercontrol arminaphase III study.22,23
However, it is noteworthy that patientswere enrolled inREGALat the
time of first recurrence, whereas these historical series included pa-
tients treated at the first, second, or later recurrences. Nevertheless,
lomustinemonotherapy demonstrates efficacy in patients with recur-
rent glioblastoma previously treated with temozolomide and should
be considered as a control arm in future comparative trials.
Although cediranib monotherapy or in combination with lo-
mustine did not improve PFS compared with lomustine alone in
REGAL, preclinical models suggest synergistic activity of anti-VEGF
therapy in combination with radiation owing to the ability of these
agents to normalize tumor vessels. On the basis of these observations,
cediranib in combinationwith chemoradiotherapy is being studied in
phase II trials in the newly diagnosed glioblastoma population24
(NCT00662506; NCT01062425).
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